Bluejay Diagnostics (NASDAQ:BJDX) Shares Down 6.2% – Time to Sell?

Shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) were down 6.2% on Friday . The stock traded as low as $1.29 and last traded at $1.36. Approximately 316,918 shares changed hands during mid-day trading, an increase of 455% from the average daily volume of 57,085 shares. The stock had previously closed at $1.45.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Wall Street Zen raised shares of Bluejay Diagnostics to a “sell” rating in a report on Saturday, November 1st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Monday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, Bluejay Diagnostics has a consensus rating of “Sell”.

Bluejay Diagnostics Trading Down 6.2%

The firm has a market capitalization of $2.46 million, a P/E ratio of -0.01 and a beta of 0.60. The stock has a 50-day simple moving average of $1.92 and a two-hundred day simple moving average of $1.71.

Bluejay Diagnostics (NASDAQ:BJDX) last released its quarterly earnings results on Friday, November 7th. The company reported ($1.01) earnings per share for the quarter.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.